Literature DB >> 22190288

BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma.

Sara Busacca1, Michael Sheaff, Kenneth Arthur, Steven G Gray, Kenneth J O'Byrne, Derek J Richard, Alex Soltermann, Isabelle Opitz, Harvey Pass, D Paul Harkin, Jennifer E Quinn, Dean A Fennell.   

Abstract

Therapeutic options for malignant pleural mesothelioma (MPM) are limited despite the increasing incidence globally. The vinca alkaloid vinorelbine exhibits clinical activity; however, to date, treatment optimization has not been achieved using biomarkers. BRCA1 regulates sensitivity to microtubule poisons; however, its role in regulating vinorelbine-induced apoptosis in mesothelioma is unknown. Here we demonstrate that BRCA1 plays an essential role in mediating vinorelbine-induced apoptosis, as evidenced by (1) the strong correlation between vinorelbine sensitivity and BRCA1 expression level; (2) induction of resistance to vinorelbine by BRCA1 using siRNA oligonucleotides; (3) dramatic down-regulation of BRCA1 following selection for vinorelbine resistance; and (4) the re-activation of vinorelbine-induced apoptosis following re-expression of BRCA1 in resistant cells. To determine whether loss of BRCA1 expression in mesothelioma was potentially relevant in vivo, BRCA1 immunohistochemistry was subsequently performed on 144 primary mesothelioma specimens. Loss of BRCA1 protein expression was identified in 38.9% of samples. Together, these data suggest that BRCA1 plays a critical role in mediating apoptosis by vinorelbine in mesothelioma, warranting its clinical evaluation as a predictive biomarker.
Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22190288     DOI: 10.1002/path.3979

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  11 in total

1.  Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.

Authors:  Vasiliki Panou; Meghana Gadiraju; Arthur Wolin; Caroline M Weipert; Emily Skarda; Aliya N Husain; Jyoti D Patel; Buerkley Rose; Shannon R Zhang; Madison Weatherly; Viswateja Nelakuditi; Amy Knight Johnson; Maria Helgeson; David Fischer; Arpita Desai; Nanna Sulai; Lauren Ritterhouse; Oluf D Røe; Kiran K Turaga; Dezheng Huo; Jeremy Segal; Sabah Kadri; Zejuan Li; Hedy L Kindler; Jane E Churpek
Journal:  J Clin Oncol       Date:  2018-08-16       Impact factor: 44.544

2.  Activation of AKT/ERK confers non-small cell lung cancer cells resistance to vinorelbine.

Authors:  Da-Ping Fan; Yi-Mei Zhang; Xiao-Chen Hu; Jing-Jing Li; Wei Zhang
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15

3.  PTEN phosphatase-independent maintenance of glandular morphology in a predictive colorectal cancer model system.

Authors:  Ishaan C Jagan; Ravi K Deevi; Aliya Fatehullah; Rebecca Topley; Joshua Eves; Michael Stevenson; Maurice Loughrey; Kenneth Arthur; Frederick Charles Campbell
Journal:  Neoplasia       Date:  2013-11       Impact factor: 5.715

4.  Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.

Authors:  Marjorie G Zauderer; Samantha L Kass; Kaitlin Woo; Camelia S Sima; Michelle S Ginsberg; Lee M Krug
Journal:  Lung Cancer       Date:  2014-03-14       Impact factor: 5.705

5.  Resistance to HSP90 inhibition involving loss of MCL1 addiction.

Authors:  S Busacca; E W P Law; I R Powley; D A Proia; M Sequeira; J Le Quesne; A Klabatsa; J M Edwards; K B Matchett; J L Luo; J H Pringle; M El-Tanani; M MacFarlane; D A Fennell
Journal:  Oncogene       Date:  2015-06-22       Impact factor: 9.867

6.  miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma.

Authors:  Marissa Williams; Michaela B Kirschner; Yuen Yee Cheng; Jacky Hanh; Jocelyn Weiss; Nancy Mugridge; Casey M Wright; Anthony Linton; Steven C Kao; J James B Edelman; Michael P Vallely; Brian C McCaughan; Wendy Cooper; Sonja Klebe; Ruby C Y Lin; Himanshu Brahmbhatt; Jennifer MacDiarmid; Nico van Zandwijk; Glen Reid
Journal:  Oncotarget       Date:  2015-09-15

7.  Non-small cell lung cancer PC-9 cells exhibit increased sensitivity to gemcitabine and vinorelbine upon acquiring resistance to EGFR-tyrosine kinase inhibitors.

Authors:  Junko Hamamoto; Hiroyuki Yasuda; Kaito Aizawa; Makoto Nishino; Shigenari Nukaga; Toshiyuki Hirano; Ichiro Kawada; Katsuhiko Naoki; Tomoko Betsuyaku; Kenzo Soejima
Journal:  Oncol Lett       Date:  2017-07-18       Impact factor: 2.967

Review 8.  An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma.

Authors:  Alexander Davis; Helen Ke; Steven Kao; Nick Pavlakis
Journal:  Lung Cancer (Auckl)       Date:  2022-03-02

Review 9.  Fibrosis in Mesothelioma: Potential Role of Lysyl Oxidases.

Authors:  Lara Perryman; Steven G Gray
Journal:  Cancers (Basel)       Date:  2022-02-15       Impact factor: 6.639

10.  PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1.

Authors:  Giulia Pinton; Arcangela Gabriella Manente; Bruno Murer; Elvira De Marino; Luciano Mutti; Laura Moro
Journal:  J Cell Mol Med       Date:  2013-01-10       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.